

+GC
-GC
Surviving Fraction
1
0.1
0.01
0.0
0.2
0.4
0.6
0.8
1.0
Cisplatin Dose (μM)

FIG. 1



CAT -GC
CAT +GC
wt -GC
wt +GC
Surviving Fraction
1
0.1
0.01
0
2
4
6
8
Cisplatin Dose (μM)

FIG. 2



1.0
0.8
0.6
0.4
0.2
0.0
Ratio
Untreated
GC4419
Cisplatin
Cisplatin+ GC4419
Treatment Group

FIG. 3



0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
89 kDa/116 kDa Ratio
Untreated
GC4419
Cisplatin
Cisplatin+ GC4419
Treatment Group

FIG. 4



1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Ratio
IR+ GC4419
IR+ Cisplatin
IR+ Cisplatin+ GC4419
Treatment Group

FIG. 5



1.0
0.8
0.6
0.4
0.2
0.0
89 kDa/116 kDa Ratio
IR
IR+ GC4419
IR+ Cisplatin
IR+ Cisplatin+ GC4419
Treatment Group

FIG. 6A



0.16
0.14
0.12
0.10
0.08
0.06
0.04
0.02
0.00
Ratio
p<.01
Untreated
GC4419
Cisplatin
Cisplatin+ GC4419
Treatment Group

FIG. 6B



0.30
0.25
0.20
0.15
0.10
0.05
0.00
Ratio
p<.001
p<.05
IR
IR+ GC4419
IR+ Cisplatin
IR+ Cisplatin+ GC4419
Treatment Group

FIG. 6C



H460
50000
40000
30000
20000
10000
0
Mean Signal Intensity
p<.01
Untreated
GC4419
Cisplatin
Cisplatin+ GC4419
Treatment Group

FIG. 7A



H1299wt
30000
25000
20000
15000
10000
5000
0
Mean Signal Intensity
p<.01
Untreated
GC4419
Cisplatin
Cisplatin+ GC4419
Treatment Group

FIG. 7B



H460
Mean Signal Intensity
50000
40000
30000
20000
10000
0
p<.05
p<.01
IR
IR + GC4419
IR + Cisplatin
IR + Cisplatin+ GC4419
Treatment Group

FIG. 7C



H1299wt
Mean Signal Intensity
35000
30000
25000
20000
15000
10000
5000
0
p<.01
IR
IR + GC4419
IR + Cisplatin
IR + Cisplatin+ GC4419
Treatment Group

FIG. 7D



H460
Mean Signal Intensity
14000
12000
10000
8000
6000
4000
2000
0
p<.01
p<.01
Untreated
GC4419
Cisplatin
Cisplatin+ GC4419
Treatment Group

FIG. 8A



H1299wt
Mean Signal Intensity
10000
8000
6000
4000
2000
0
p<.01
p<.05
Untreated
GC4419
Cisplatin
Cisplatin+ GC4419
Treatment Group

FIG. 8B



H460
Mean Signal Intensity
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
p<.05
p<.05
IR
IR + GC4419
IR + Cisplatin
IR + Cisplatin+ GC4419
Treatment Group

FIG. 8C



H1299wt
Mean Signal Intensity
16000
14000
12000
10000
8000
6000
4000
2000
0
p<.01
p<.01
IR
IR + GC4419
IR + Cisplatin
IR + Cisplatin+ GC4419
Treatment Group

FIG. 8D



H460
40000
30000
20000
10000
0
p<.01
Mean Signal Intensity
Untreated
GC4419
Cisplatin
Cisplatin+ GC4419
Treatment Group

FIG. 9A



H1299wt
30000
25000
20000
15000
10000
5000
0
p<.05
Mean Signal Intensity
Untreated
GC4419
Cisplatin
Cisplatin+ GC4419
Treatment Group

FIG. 9B



H460
50000
40000
30000
20000
10000
0
Mean Signal Intensity
p<.01
p<.05
IR
IR + GC4419
IR + Cisplatin
IR + Cisplatin+ GC4419
Treatment Group

FIG. 9C



H1299wt
40000
30000
20000
10000
0
Mean Signal Intensity
p<.01
p<.01
IR
IR + GC4419
IR + Cisplatin
IR + Cisplatin+ GC4419
Treatment Group

FIG. 9D



BUN Levels in Young
Young Control
Young GC4419
Young Cisplatin
Young Cis+GC4419
BUN (mg/dL)
100
50
0
Baseline
Day 3
(Days)
BUN Levels in Old
Old Control
Old GC4419
Old Cisplatin
Old Cis+GC4419
150
100
50
0
****
n=5, ****=p<0.0001
Crea Levels in Young
Creatinine (mg/dL)
0.5
0.4
0.3
0.2
0.1
0.0
Crea Levels in Old
3
2
1
0
n=5, *=p<0.05
*

FIG. 10A



Kim1_Kranti A1-A20_young mice
*
250
200
150
100
50
0
-50
Fold Change
Vehicle
GC4419
Cisplatin (1x)
Cisplatin (1x) GC4419
NGAL_Kranti A1-A20_young mice
*
200
150
100
50
0
-50
Fold Change
Vehicle
GC4419
Cisplatin (1x)
Cisplatin (1x) GC4419

FIG. 10B




FIG. 10C




FIG. 10D




FIG. 11A




FIG. 11B



Neutrophil Count
10^3 cells/µL
4
3
2
1
0
*#
*
Control
Cis + IR
GC + Cis + IR
2 Days Post-treatment
Neutrophil Count
15
10
5
0
##
Cis + IR
Cis + IR +GC
2 wks Post-treatment
Neutrophil Percent
Neutrophil %
80
60
40
20
0
Control
Cis + IR
Cis + IR +GC
2 Days Post-treatment
Neutrophil Percent
#
Cis + IR
Cis + IR +GC
2 wks Post-treatment

FIG. 11C



Eosinophil Percent
Eosinophil %
100
80
60
40
20
0
Control
Cis + IR
Cis + IR +GC
2 Days Post-treatment
Eosinophil Percent
Eosinophil %
100
80
60
40
20
0
##
Cis + IR
Cis + IR +GC
2 wks Post-treatment

FIG. 11D